Tumor DNA >200 ng or FFPE block/slides with at least 20% tumor. Matched normal tissue is required for MSI analysis and for selected germline distinctions.
TUMOR DIAGNOSTICS
CancerEssential
Entity-specific DNA panels for frequent therapy-relevant variants, selected structural variants, and optional MSI analysis.
Entity-specific NGS at approximately 1,000× average coverage; selected structural variants and five-marker MSI PCR where applicable.
Therapy-relevant variants within the chosen entity panel, structural variants, MSI where ordered, and clinical interpretation.
Typically 2–3 weeks after accepted sample receipt.
CLINICAL VALUE
Where this test is strongest
✓14 entity-specific configurations
✓Approximately 1,000× average coverage
✓Sensitivity >99.8% and specificity >99.9% under referenced high-quality ≥20% tumor validation conditions
✓Selected structural variants included for most panels
LIMITATIONS
What must remain visible
!Only the chosen subpanel is analyzed; rare or unexpected drivers outside it can be missed.
!A comprehensive profile may be preferable after treatment failure, an unusual tumor, or a broad therapy question.
GENE & ANALYTICAL SCOPE
69 published genes
Select a tumor entity to see its exact code and gene list.
MelanomaPAT01 · 8 published genes+
8-gene entity-focused DNA panel.
BRAFCDKN2AGNA11GNAQKITNRASTERTTP53
Colorectal cancerPAT02 · 19 published genes+
19-gene entity-focused DNA panel.
AKT1BRAFCTNNB1EGFRERBB2FBXW7KRASMLH1MSH2MSH6NRASPIK3CAPMS2POLD1POLEPTENRETSMAD4TP53
Lung cancerPAT03 · 19 published genes+
19 DNA genes plus ALK, RET, and ROS1 translocation analysis.
AKT1ALKBRAFEGFRERBB2FBXW7FGFR1FGFR2FGFR3KRASMAP2K1METNOTCH1NRASPIK3CAPTENRETROS1TP53
GISTPAT04 · 8 published genes+
8-gene gastrointestinal stromal tumor panel.
BRAFKITPDGFRASDHASDHBSDHCSDHDTP53
GliomaPAT05 · 11 published genes+
11-gene glioma-focused panel.
ATRXBRAFEGFRH3-3AH3C2IDH1IDH2PIK3CAPTENTERTTP53
Breast / ovarian cancerPAT06 · 15 published genes+
15-gene breast and ovarian tumor panel.
AKT1ATMBARD1BRCA1BRCA2BRIP1CHEK2ERBB2ESR1PALB2PIK3CAPTENRAD51CRAD51DTP53
Thyroid cancerPAT07 · 9 published genes+
9-gene thyroid tumor panel.
ALKBRAFHRASKRASNRASPIK3CARETTERTTP53
CholangiocarcinomaPAT09 · 6 published genes+
6-gene biliary tract tumor panel.
FGFR2IDH1IDH2KRASPIK3CATP53
Pancreatic cancerPAT10 · 9 published genes+
9-gene pancreatic tumor panel.
BRCA1BRCA2CDKN2ACHEK2ERBB4KRASPALB2SMAD4TP53
BRCA1 / BRCA2PAT11 · 2 published genes+
Tumor-only, normal-tissue with MLPA, or tumor–normal with MLPA pathways.
BRCA1BRCA2
Prostate cancerPAT12 · 24 published genes+
24-gene prostate tumor panel.
ATMATRBARD1BRCA1BRCA2BRIP1CDK12CHEK1CHEK2FANCAFANCLMLH1MRE11MSH2MSH6NBNPALB2PMS2RAD51BRAD51CRAD51DRAD54LSPOPTP53
Gastric cancerPAT13 · 18 published genes+
18-gene gastric tumor panel.
AKT1ATMBRAFBRCA1BRCA2CHEK2CTNNB1ERBB2KRASMLH1MSH2MSH6NRASPIK3CAPMS2PTENSMAD4TP53
Mismatch repairPAT14 · 4 published genes+
Focused DNA mismatch-repair gene panel.
MLH1MSH2MSH6PMS2
Endometrial cancerPAT15 · 9 published genes+
9-gene endometrial tumor panel.
KRASMLH1MSH2MSH6PMS2POLD1POLEPTENTP53
Structural variants8 published genes+
Selected structural variants evaluated with PAT01–PAT10 and PAT12–PAT15.
ALKBRAFFGFR1FGFR2FGFR3METRETROS1
MSI markers5 published genes+
Microsatellite instability analysis by PCR.
BAT25BAT26NR21NR22NR27
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.